In one of the largest prevalence studies to date, researchers from the U.K. provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings published in Hepatology, a journal of the American Association for the Study of Liver Diseases, indicate that genotype 1 is the most prevalent worldwide, with over 83 million patients infected of which one-third reside in East Asia. Genotype 3, at just over 54 million cases, is the next most prevalent, followed by genotypes 2, 4, 6, and 5.
Despite efforts to control HCV, it remains one of the most prevalent diseases globally, with up to 150 million patients living with chronic infection according to the World Health Organization (WHO). Previous research shows that chronic HCV leads to the development liver cirrhosis, hepatocellular carcinoma (HCC) or liver cancer, liver failure and death. WHO reports that 350,000 to 500,000 deaths each year are caused by liver diseases related to HCV.
"While the HCV infection rate is decreasing in developed countries, deaths from liver disease secondary to HCV will continue increasing over the next 20 years," explains lead co-author Dr. Jane Messina with the University of Oxford in the U.K. "Understanding the global trends in the genetic makeup of HCV is the focus of our study and imperative in developing new treatment strategies that may save millions of lives around the world."
Researchers identified 1,217 medical studies between 1989 (the year HCV was discovered) and 2013 that reported HCV genotypes. The data were then combined with HCV prevalence estimates from the WHO Global Burden of Disease project. Roughly 90% of the global population, representing 117 countries was included in this study.
Analysis shows that HCV genotype 1 is the most prevalent at 46% of all HCV cases, followed by genotype 3 at 30%; genotypes 2, 4, and 6 with a combined total of 23% and genotype 5 at less than 1%. Researchers highlight that genotypes 1 and 3 are most dominant regardless economic status, but found lower-income countries had larger concentrations of genotypes 4 and 5.
Dr. Eleanor Barnes with the University of Oxford adds: "The testing of new therapeutics is still dependent upon knowledge of viral genotype. Non-genotype 1 HCV, comprises more than half of all HCV cases. Our study provides evidence of genotype prevalence for specific countries and regions that will help improve access to new viral therapies to combat HCV."
Monday, July 28, 2014 is World Hepatitis Day--a day organized by WHO to increase awareness and understanding of viral hepatitis.
This study is published in Hepatology. Media wishing to receive a PDF of this article may contact email@example.com.
Full citation: "The Global Distribution and Prevalence of HCV Genotypes." Jane P. Messina, Isla Humphreys, Abraham Flaxman, Anthony Brown, Graham S. Cooke, Oliver G. Pybus and Eleanor Barnes. Hepatology; (DOI: 10.1002/hep.27259) Online Publicatione: July 28, 2014.
URL Upon Publication: http://doi.
Author Contacts: Media wishing to speak with Drs. Barnes or Messina may contact Carole Scott firstname.lastname@example.org; +44 1865 287438 or Sally-Anne Stewart at email@example.com; +44 1865 287429.
About the Journal
Hepatology is the premier publication in the field of liver disease, publishing original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism. Hepatology is published on is published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD). For more information, please visit http://wileyonlinelibrary.
Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.
Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's website can be accessed at http://www.